Essential Medicinal Chemistry of Essential Medicines
Open accessThe DOI matches its Crossref record; 66 of the 68 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
Since 1977, the World Health Organization publishes a list of essential medicines, i.e., those that satisfy the priority health care needs of the population and are selected with regard to disease prevalence and public health relevance, evidence of clinical efficacy, and safety, as well as comparative costs and cost-effectiveness. The Essential Medicines List (EML) is an invaluable tool for all countries to select those medicines that have an excellent risk/benefit ratio and that are reputed to be of pivotal importance to health. In the present perspective, we describe the chemical composition and the main features of the small molecules that are included in the EML, spanning from their origin, to their stereochemistry and measure of drug-likeness. Most and foremost, we wish to disseminate the importance of the EML, which can be both a helpful teaching tool in an ever-expanding world of medicines and an inspiration for those involved in pharmaceutical R&D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“N2O is one of the World Health Organization’s essential medicines, and its clinical administration has been considered safe for more than 150 years [125].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [125]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
Meanwell, N. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01788 · Cited by 2,655
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
Hawkins, P. C. D., Skillman, A. G., Warren, G. L., Ellingson, B. A., & Stahl, M. T. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100031x · Cited by 1,607
Ilardi, E. A., Vitaku, E., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401375q · Cited by 1,604
The 500 Dalton rule for the skin penetration of chemical compounds and drugs
Bos, J. D., & Meinardi, M. M. H. M. (2000) · Experimental Dermatology · doi:10.1034/j.1600-0625.2000.009003165.x · Cited by 1,465
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Sackett, D. L. (1997) · Seminars in Perinatology · doi:10.1016/s0146-0005(97)80013-4 · Cited by 1,061
Analysis of US FDA-Approved Drugs Containing Sulfur Atoms
Scott, K. A., & Njardarson, J. T. (2018) · Topics in Current Chemistry · doi:10.1007/s41061-018-0184-5 · Cited by 1,036
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Drug permeation through human skin: Theory and invitro experimental measurement
Michaels, A. S., Chandrasekaran, S. K., & Shaw, J. E. (1975) · AIChE Journal · doi:10.1002/aic.690210522 · Cited by 801
Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Central nervous system multiparameter optimization desirability: Application in drug discovery
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00029 · Cited by 653
The blood-brain barrier: Physiology and strategies for drug delivery
Pandit, R., Chen, L., & Götz, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.009 · Cited by 651
Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017—Utility and Limitations
Baell, J. B., & Nissink, J. W. M. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00903 · Cited by 648
A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups
Kalgutkar, A., Gardner, I., Obach, R., Shaffer, C., Callegari, E., Henne, K., Mutlib, A., Dalvie, D., Lee, J., Nakai, Y., et al. (2005) · Current Drug Metabolism · doi:10.2174/1389200054021799 · Cited by 616
Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology
Ari�ns, E. J. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541922 · Cited by 609
Chiral Toxicology: It's the Same Thing…Only Different
Smith, S. W. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp097 · Cited by 602
FDA'S policy statement for the development of new stereoisomeric drugs
(1992) · Chirality · doi:10.1002/chir.530040513 · Cited by 581
The discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514
In silico prediction of blood–brain barrier permeation
Clark, D. E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02827-7 · Cited by 483
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
CNS Drug Design Based on Principles of Blood‐Brain Barrier Transport
Pardridge, W. M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70051781.x · Cited by 460
Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Shultz, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00686 · Cited by 434
Sneader, W. (2005) · Wiley eBooks · doi:10.1002/0470015535 · Cited by 427
Delost, M. D., Smith, D. T., Anderson, B. J., & Njardarson, J. T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00876 · Cited by 409
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection: Miniperspective
DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00717 · Cited by 378
Smith, B. R., Eastman, C. M., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501105n · Cited by 372
Classifying antibiotics in the WHO essential medicines list for optimal use—be AWaRe
Sharland, M., Pulcini, C., Harbarth, S., Zeng, M., Gandra, S., Mathur, S., & Magrini, N. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30724-7 · Cited by 336
The Blood–Brain Barrier (BBB) Score
Gupta, M., Lee, H. J., Barden, C. J., & Weaver, D. F. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01220 · Cited by 332
25 years of the WHO essential medicines lists: progress and challenges
Laing, R., Waning, B., Gray, A., Ford, N., & 't Hoen, E. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13375-2 · Cited by 321
Fluorine-containing natural products
O’Hagan, D., & B. Harper, D. (1999) · Journal of Fluorine Chemistry · doi:10.1016/s0022-1139(99)00201-8 · Cited by 318
A Survey of the Structures of US FDA Approved Combination Drugs
Das, P., Delost, M. D., Qureshi, M. H., Smith, D. T., & Njardarson, J. T. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01610 · Cited by 312
The 4F2hc/LAT1 complex transports l-DOPA across the blood–brain barrier
Kageyama, T., Nakamura, M., Matsuo, A., Yamasaki, Y., Takakura, Y., Hashida, M., Kanai, Y., Naito, M., Tsuruo, T., Minato, N., et al. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02758-x · Cited by 298
Bedaquiline: First FDA-approved tuberculosis drug in 40 years
Mahajan, R. (2013) · International Journal of Applied and Basic Medical Research · doi:10.4103/2229-516x.112228 · Cited by 271
Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting
Zhu, F., Qin, C., Tao, L., Liu, X., Shi, Z., Ma, X., Jia, J., Tan, Y., Cui, C., Lin, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107336108 · Cited by 255
Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe
Sharland, M., Pulcini, C., Harbarth, S., Zeng, M., Gandra, S., Mathur, S., & Magrini, N. (2018) · Archive ouverte UNIGE (University of Geneva) · Cited by 211
Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems
Tsuji, A. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.54 · Cited by 209
Metabolic activation and drug toxicity
Nelson, S. D. (1982) · Journal of Medicinal Chemistry · doi:10.1021/jm00349a001 · Cited by 203
Designing around Structural Alerts in Drug Discovery
Kalgutkar, A. S. S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00917 · Cited by 173
History of the Development and Evolution of Local Anesthesia Since the Coca Leaf
Calatayud, J., & González, Á. (2003) · Anesthesiology · doi:10.1097/00000542-200306000-00031 · Cited by 171
Drug delivery to hair follicles
Patzelt, A., & Lademann, J. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.776038 · Cited by 170
Acharya, N. K., Goldwaser, E. L., Forsberg, M. M., Godsey, G. A., Johnson, C. A., Sarkar, A., DeMarshall, C. A., Kosciuk, M. C., Dash, J., Hale, C. P., et al. (2015) · Brain Research · doi:10.1016/j.brainres.2015.04.054 · Cited by 132
Making medicines essential: The emergent centrality of pharmaceuticals in global health
Greene, J. A. (2011) · BioSocieties · doi:10.1057/biosoc.2010.39 · Cited by 129
Recent Advances in the Prediction of Blood–Brain Partitioning from Molecular Structure
Lobell, M., Molnár, L. M., & Keserű, G. M. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10282 · Cited by 119
Why Some Targets Benefit from beyond Rule of Five Drugs
Egbert, M., Whitty, A., Keserű, G. M., & Vajda, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01732 · Cited by 118
From Racemates to Single Enantiomers – Chiral Synthetic Drugs over the last 20 Years
Murakami, H. (2006) · Topics in current chemistry · doi:10.1007/128_2006_072 · Cited by 98
Liu, R., Yu, X., & Wallqvist, A. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0053-y · Cited by 92
Griffin, L., Annaert, P., & Brouwer, K. L. R. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22655 · Cited by 63
Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs
Gunaydin, H. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00390 · Cited by 55
Inside the isomers: the tale of chiral switches
Somogyi, A. A., Bochner, F., & Foster, D. J. R. (2004) · Australian Prescriber · doi:10.18773/austprescr.2004.039 · Cited by 50
Zhu, H., Lemos, H. D. P., Bhatt, B., Islam, B. N., Singh, A., Gurav, A., Huang, L., Browning, D. D., Mellor, A. L., Fulzele, S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183484 · Cited by 50
Ghose, A. K., Ott, G. R., & Hudkins, R. L. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00273 · Cited by 43
Homochiral Drug Design and Development by Racemization
Ali, I. (2007) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620707781662835 · Cited by 12
Preparation of Water-Soluble Compounds by Covalent Attachment of Solubilizing Moieties
Wermuth, C. G., & Lesuisse, D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00030-4 · Cited by 10
Structural diversity in ligand recognition by GPCRs
Jakowiecki, J., Miszta, P., Niewieczerzał, S., & Filipek, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816228-6.00003-9 · Cited by 8
Ishii, H. (2017) · Springer eBooks · doi:10.1007/978-4-431-56526-0_22 · Cited by 8
Preparation of Water-Soluble Compounds by Covalent Attachment of Solubilizing Moieties
Wermuth, C. G. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374194-3.00038-x · Cited by 8
Plant Product Analogues and Compounds Derived from Them
Sneader, W. (2005) · Drug Discovery · doi:10.1002/0470015535.ch11 · Cited by 6
Research works printed but not linked: 4
- 2020, OMEGA2
- Csuk, 2007, Biocatalysis in the Pharma and Biotech Industries, 699
- Hutt, 2003, The chiral switch: The development of single enantiomer drugs from racemates, Acta Fac. Pharm. Univ. Comen., 50, 7
- 2018, Chemaxon Calculator Plugins
Cited by
Phenols in Pharmaceuticals: Analysis of a Recurring Motif
Scott, K. A., Cox, P. B., & Njardarson, J. T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00223 · Cited by 206
Exploring Electrochemical C(sp 3 )–H Oxidation for the Late-Stage Methylation of Complex Molecules
Novaes, L. F. T., Ho, J. S. K., Mao, K., Liu, K., Tanwar, M., Neurock, M., Villemure, E., Terrett, J. A., & Lin, S. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c09412 · Cited by 168
Pyrazine and Phenazine Heterocycles: Platforms for Total Synthesis and Drug Discovery
Huigens, R. W., Brummel, B. R., Tenneti, S., Garrison, A. T., & Xiao, T. (2022) · Molecules · doi:10.3390/molecules27031112 · Cited by 87
Click 1,2,3-triazoles in drug discovery and development: From the flask to the clinic?
Serafini, M. T., Pirali, T., & Tron, G. C. (2020) · Advances in heterocyclic chemistry · doi:10.1016/bs.aihch.2020.10.001 · Cited by 49
Self-citationPharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“N 2 O is one of the World Health Organization’s essential medicines, and its clinical administration has been considered safe for more than 150 years [125].”
Background
Metadata
- Authors
- Serafini, M., Cargnin, S., Massarotti, A., Pirali, T., & Genazzani, A. A.
- Affiliations
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Corresponding author
- Pirali, Tracey
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-04-30
- Volume
- 63
- Issue
- 18
- Pages
- 10170-10187
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC8007110
- OpenAlex
- W3021755458
- Cited by
- 46
- References
- 67
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 12 · 2023: 6 · 2022: 8 · 2021: 9 · 2020: 3
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Medicinal Chemistry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Ministero dell???Istruzione, dell???Universit?? e della Ricerca (2017CBNCYT, 2017WJZ9W9)
- Associazione Italiana per la Ricerca sul Cancro (22568)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Medical and Pharmaceutic Studies
- Keywords
- essential medicines, WHO Model List of Essential Medicines, small molecules, stereochemistry, drug-likeness, pharmaceutical R&D, drug selection, cost-effectiveness
- MeSH terms
- Administration, Oral, Chemistry, Pharmaceutical, Formularies as Topic, Humans, Injections, Stereoisomerism, World Health Organization, Molecular Structure, Drugs, Essential
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.